Journal article
Whole-body Sleeping Beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality
Cancer research (Chicago, Ill.), Vol.69(21), pp.8429-8437
11/01/2009
DOI: 10.1158/0008-5472.CAN-09-1760
PMCID: PMC2771123
PMID: 19843846
Abstract
The
Sleeping Beauty
(SB) transposon system has been used as a somatic mutagen to identify candidate cancer genes. In previous studies, efficient leukemia/lymphoma formation on an otherwise wild-type genetic background occurred in mice undergoing whole-body mobilization of transposons, but was accompanied by high levels of embryonic lethality. To explore the utility of SB for large-scale cancer gene discovery projects, we have generated mice that carry combinations of different transposon and transposase transgenes. We have identified a transposon/transposase combination that promotes highly penetrant leukemia/lymphoma formation on an otherwise wild-type genetic background, yet does not cause embryonic lethality. Infiltrating gliomas also occurred at lower penetrance in these mice. SB-induced or accelerated tumors do not harbor large numbers of chromosomal amplifications or deletions, indicating that transposon mobilization likely promotes tumor formation by insertional mutagenesis of cancer genes, and not by promoting wide-scale genomic instability. Cloning of transposon insertions from lymphomas/leukemias identified common insertion sites at known and candidate novel cancer genes. These data indicate that a high mutagenesis rate can be achieved using SB without high levels of embryonic lethality or genomic instability. Furthermore, the SB system can be used to identify new genes involved in lymphomagenesis/leukemiogenesis.
Details
- Title: Subtitle
- Whole-body Sleeping Beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality
- Creators
- Lara S Collier - Department of Genetics, Cell Biology and Development; Masonic Cancer Center; University of Minnesota; Minneapolis, MNDavid J Adams - Wellcome Trust Sanger Institute; Hinxton, Cambridge, UKChristopher S Hackett - University of California; San Francisco, CALaura E Bendzick - Department of Genetics, Cell Biology and Development; Masonic Cancer Center; University of Minnesota; Minneapolis, MNKeiko Akagi - Mouse Cancer Genetics Program; National Cancer Institute at Frederick; Frederick, MDMichael N Davies - Department of Genetics, Cell Biology and Development; Masonic Cancer Center; University of Minnesota; Minneapolis, MNMiechaleen D Diers - Department of Genetics, Cell Biology and Development; Masonic Cancer Center; University of Minnesota; Minneapolis, MNFausto J Rodriguez - Division of Experimental Pathology; Mayo Clinic; Rochester, MNAaron M Bender - Division of Experimental Pathology; Mayo Clinic; Rochester, MNChristina Tieu - Division of Experimental Pathology; Mayo Clinic; Rochester, MNIlze Matise - Masonic Cancer, Center Histopathology Core; University of Minnesota; Minneapolis, MNAdam J Dupuy - Department of Anatomy and Cell Biology; University of Iowa; Iowa City, IANeal G Copeland - Institute of Molecular and Cell Biology; SingaporeNancy A Jenkins - Institute of Molecular and Cell Biology; SingaporeJ. Graeme Hodgson - University of California; San Francisco, CAWilliam A Weiss - University of California; San Francisco, CARobert B Jenkins - Division of Experimental Pathology; Mayo Clinic; Rochester, MNDavid A Largaespada - Department of Genetics, Cell Biology and Development; Masonic Cancer Center; University of Minnesota; Minneapolis, MN
- Resource Type
- Journal article
- Publication Details
- Cancer research (Chicago, Ill.), Vol.69(21), pp.8429-8437
- DOI
- 10.1158/0008-5472.CAN-09-1760
- PMID
- 19843846
- PMCID
- PMC2771123
- NLM abbreviation
- Cancer Res
- ISSN
- 0008-5472
- eISSN
- 1538-7445
- Language
- English
- Date published
- 11/01/2009
- Academic Unit
- Anatomy and Cell Biology; Pathology
- Record Identifier
- 9984025477402771
Metrics
10 Record Views